Hirsch William, Fischer Monika, Khoruts Alexander, Allegretti Jessica R, Kelly Colleen R, Vaughn Byron
Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Open Forum Infect Dis. 2025 Mar 7;12(3):ofaf130. doi: 10.1093/ofid/ofaf130. eCollection 2025 Mar.
Recurrent infection (CDI) is primarily driven by antibiotic-induced disruption of the indigenous intestinal microbiota. Restoration of microbiota through fecal microbiota transplantation (FMT) is effective in preventing subsequent CDI, although this effect is attenuated with additional antibiotic exposure. The aim of this study was to identify the risk factors for recurrent antibiotic administration after FMT.
This is a prospective cohort of patients who were administered FMT for recurrent CDI from 1 July 2019 through 23 November 2023 across 6 institutions in the United States. Providers collected de-identified data at the time of FMT administration and in the months post-FMT administration.
The analysis included 448 patients. Risk factors for non-CDI antibiotic administration within 2 months of FMT included immunocompromised status (odds ratio [OR], 2.2 [95% confidence interval {CI}, 1.1-4.4]; = .02), >3 non-CDI antibiotic courses pre-FMT (OR, 3.1 [95% CI, 1.4-6.8]; = .006), and prior hospitalization for CDI (OR, 2.0 [95% CI, 1.1-3.8]; = .02). The most common indications for non-CDI antibiotic administration post-FMT were urinary tract infections, respiratory infections, and procedure prophylaxis.
Non-CDI antibiotic exposure significantly increases the risk of CDI recurrence post-FMT. Risk factors for non-CDI antibiotic administration within 2 months of FMT include immunocompromised status, multiple prior non-CDI antibiotics, and prior hospitalization for CDI. These individuals may benefit from additional or modified recurrent CDI prevention strategies.
复发性艰难梭菌感染(CDI)主要由抗生素引起的肠道固有微生物群破坏所致。通过粪便微生物群移植(FMT)恢复微生物群对预防后续CDI有效,尽管这种效果会因额外的抗生素暴露而减弱。本研究的目的是确定FMT后再次使用抗生素的危险因素。
这是一项前瞻性队列研究,研究对象为2019年7月1日至2023年11月23日期间在美国6家机构接受FMT治疗复发性CDI的患者。医护人员在FMT给药时以及FMT给药后的几个月收集了去识别化的数据。
分析纳入了448例患者。FMT后2个月内使用非CDI抗生素的危险因素包括免疫功能低下状态(比值比[OR],2.2[95%置信区间{CI},1.1 - 4.4];P = 0.02)、FMT前>3个非CDI抗生素疗程(OR,3.1[95%CI,1.4 - 6.8];P = 0.006)以及既往因CDI住院(OR,2.0[95%CI,1.1 - 3.8];P = 0.02)。FMT后使用非CDI抗生素最常见的指征是尿路感染、呼吸道感染和手术预防。
非CDI抗生素暴露显著增加FMT后CDI复发的风险。FMT后2个月内使用非CDI抗生素的危险因素包括免疫功能低下状态、多个既往非CDI抗生素疗程以及既往因CDI住院。这些个体可能受益于额外的或改良的复发性CDI预防策略。